UCB Stock Overview
A biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
UCB SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €136.30 |
| 52 Week High | €198.95 |
| 52 Week Low | €118.10 |
| Beta | 0.33 |
| 1 Month Change | -24.15% |
| 3 Month Change | -25.32% |
| 1 Year Change | 12.46% |
| 3 Year Change | 24.30% |
| 5 Year Change | 65.49% |
| Change since IPO | 44,568.61% |
Recent News & Updates
Why We Think UCB SA's (EBR:UCB) CEO Compensation Is Not Excessive At All
Apr 18
UCB SA's (EBR:UCB) Share Price Is Still Matching Investor Opinion Despite 25% Slump
Apr 17We Think UCB (EBR:UCB) Can Manage Its Debt With Ease
Mar 28Recent updates
Why We Think UCB SA's (EBR:UCB) CEO Compensation Is Not Excessive At All
Apr 18UCB SA's (EBR:UCB) Share Price Is Still Matching Investor Opinion Despite 25% Slump
Apr 17We Think UCB (EBR:UCB) Can Manage Its Debt With Ease
Mar 28UCB's (EBR:UCB) Earnings Are Of Questionable Quality
Mar 07
BIMZELX's Successful Launch Will Expand Future Market Opportunities In Dermatology And Rheumatology
Mar 02 UCB's new product launches and high R&D success rate are driving anticipated revenue and margin growth across global markets.UCB SA Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Mar 02UCB SA (EBR:UCB) Not Lagging Market On Growth Or Pricing
Feb 28Is UCB (EBR:UCB) A Risky Investment?
Dec 24Why We're Not Concerned About UCB SA's (EBR:UCB) Share Price
Oct 22These 4 Measures Indicate That UCB (EBR:UCB) Is Using Debt Reasonably Well
Sep 10Analysts Have Made A Financial Statement On UCB SA's (EBR:UCB) Half-Yearly Report
Jul 28Investors Still Waiting For A Pull Back In UCB SA (EBR:UCB)
Jul 15Shareholder Returns
| UCB | BE Pharmaceuticals | BE Market | |
|---|---|---|---|
| 7D | 2.1% | 2.5% | 4.2% |
| 1Y | 12.5% | -16.7% | 2.5% |
Return vs Industry: UCB exceeded the Belgian Pharmaceuticals industry which returned -16.2% over the past year.
Return vs Market: UCB exceeded the Belgian Market which returned 3% over the past year.
Price Volatility
| UCB volatility | |
|---|---|
| UCB Average Weekly Movement | 6.5% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in BE Market | 8.4% |
| 10% least volatile stocks in BE Market | 2.6% |
Stable Share Price: UCB's share price has been volatile over the past 3 months compared to the Belgian market.
Volatility Over Time: UCB's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of Belgian stocks.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1925 | 9,215 | Jean-Christophe Tellier | www.ucb.com |
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company’s primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
UCB SA Fundamentals Summary
| UCB fundamental statistics | |
|---|---|
| Market cap | €25.90b |
| Earnings (TTM) | €1.07b |
| Revenue (TTM) | €6.15b |
24.3x
P/E Ratio4.2x
P/S RatioIs UCB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UCB income statement (TTM) | |
|---|---|
| Revenue | €6.15b |
| Cost of Revenue | €1.75b |
| Gross Profit | €4.40b |
| Other Expenses | €3.34b |
| Earnings | €1.07b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 5.60 |
| Gross Margin | 71.52% |
| Net Profit Margin | 17.31% |
| Debt/Equity Ratio | 28.1% |
How did UCB perform over the long term?
See historical performance and comparisonDividends
1.0%
Current Dividend Yield25%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/19 08:13 |
| End of Day Share Price | 2025/04/17 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
UCB SA is covered by 50 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mark van der Geest | ABN AMRO Bank N.V. |
| Kamla Singh | AlphaValue |
| Brian Bourdot | Barclays |